Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer.

e15702 Background: To evaluate prognostic factors for patients with advanced gastric cancer treated by Third-line chemotherapy, and to identify the characteristics of long-term survivors. Methods: Eighty seven advanced gastric adenocarcinoma patients, who received third-line chemotherapy, were enrolled in this retrospective study from January 2010 until December 2014. Univariate and multivariate analyses were created using log-rank tests and Cox’s proportional hazard model, respectively. Results: In univariate and multivariate analyses, poor prognostic factor were investigated and four independent factors were found to be associated with poor overall survival: time-to progression under first-line chemotherapy≤6 months (HR, 1.64; 95% CI, 1.18–2.25; P ≤ 0.01), CA 19-9 level > 50 ng/ml (HR, 1.78; 95% CI, 1.32–2.67; P ≤0.007), the presence of ascites (HR, 1.67; 95% CI 1.295– 2.37, P ≤0.001), the presence of greater than or equal to three metastatic sites of disease (HR, 1.45; 95% CI 1.19– 2.19, P ≤0.004). 87 patients were classified as low-risk group( no risk factor), intermediate-risk group (one to two risk factors), high- risk group (three to four risk factor), and median survival times for each groups were 14.3 months, 12.1 months, and 7.4 months, respectively (P ≤0.01). Conclusions: This model will help in selecting the patients with advanced gastric cancer who could benefit from proceeding with third-line chemotherapy.

Download Full-text

Second- and Third-Line Chemotherapy in Advanced Gastric Cancer: a Real-Life Clinical Picture

Annals of Oncology ◽

10.1093/annonc/mdu334.42 ◽

2014 ◽

Vol 25 ◽

pp. iv224

Author(s):

M. Uccello ◽

S. Cordio ◽

M. Mattina ◽

D. Sambataro ◽

C. Martines ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Clinical Picture ◽

Real Life ◽

Third Line ◽

Line Chemotherapy

Download Full-text

Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-005-0027-2 ◽

2005 ◽

Vol 57 (1) ◽

pp. 91-96 ◽

Cited By ~ 27

Author(s):

Se Hoon Park ◽

Jeeyun Lee ◽

Se Hoon Lee ◽

Joon Oh Park ◽

Kihyun Kim ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factor ◽

Advanced Gastric Cancer ◽

First Line ◽

Line Chemotherapy

Download Full-text

Real-world delivery rate to third-line chemotherapy in patients with advanced gastric cancer

Annals of Oncology ◽

10.1093/annonc/mdy375.035 ◽

2018 ◽

Vol 29 ◽

pp. vii73

Author(s):

Masayuki Ueno ◽

Akira Doi ◽

Hirokazu Mouri ◽

Hiroshi Yamamoto ◽

Motowo Mizuno

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Real World ◽

Delivery Rate ◽

Third Line ◽

Line Chemotherapy

Download Full-text

Treatment outcome and safety of docetaxel as the third-line chemotherapy in advanced gastric cancer after progression or after failure of FOLFOX and FOLFIRI-based sequential chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.4_suppl.133 ◽

2011 ◽

Vol 29 (4_suppl) ◽

pp. 133-133

Author(s):

I. Hwang ◽

J. Kang ◽

B. Park ◽

S. Park ◽

M. Jang ◽

...

Keyword(s):

Gastric Cancer ◽

Disease Progression ◽

Advanced Gastric Cancer ◽

Performance Status ◽

Progression Free Survival ◽

Salvage Chemotherapy ◽

The Third ◽

Third Line ◽

Grade 3 ◽

Line Chemotherapy

133 Background: We performed multicenter retrospective study to evaluate the activity and the safety of a docetaxel as the third-line chemotherapy in advanced gastric cancer (AGC) patients who had undergone oxaliplatin (FOLFOX) and irinotecan (FOLFIRI)-based chemotherapy regimens. Methods: Thirty-eight patients with AGC previously treated were eligible for this study. Patients received docetaxel 30 mg/m2 +/- cisplatin 30 mg/m2 IV on day 1, 8 or docetaxel 60 mg/m2 +/- cisplatin 60 mg/m2 IV on day 1 every 3 weeks until disease progression, and responses were assessed after every two cycles according to RECIST criteria and toxicity was evaluated by NCI-CTC. Results: Thirty-two out of 38 patients were evaluable for response. A total of 95.1 cycles of chemotherapy (median 2, range 0.5–7) were administered. Relative dose intensities of docetaxel and cisplatin were 93.4% and 87.8%, respectively. The overall response rate was 15.6% and the disease control rate was 50%. With a median follow-up duration of 3.1 months (range 0.3-14.3 months), 36 patients had disease progression, and 34 patients had died at the time of analysis. The median progression-free survival was 1.8 months (95% CI, 1.3–2.3 months). The median overall survival was 3.1 months (95% CI, 2.3–3.9 months). Grade 3 or 4 hematologic toxicities included neutropenia in thirteen patients (38.3%), febrile neutropenia in four patients (11.7%). and thrombocytopenia in one patient (2.9%). Other grade 3 or 4 toxicities included neuropathy in three patients (8.8%) and mucositis in two patients (5.9%). There were three treatment-related deaths (8.8%) caused by infection associated with neutropenia. Conclusions: Salvage docetaxel chemotherapy in AGC patients failed in oxaliplatin and irinotecan-based treatment is not recommend routinely. However, selected patients with good performance status and sufficient albumin levels may have derived some survival benefits from salvage chemotherapy. No significant financial relationships to disclose.

Download Full-text